The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.
Led by Professor Tomáš Hanke at the Jenner Institute at University of Oxford, GREAT is a collaboration between Oxford University, Imperial College London, the International AIDS Vaccine Initiative (IAVI), the Kenya AIDS Vaccine Initiative - Institute for Clinical Research (KAVI-ICR), The Kenya Medical Research Institute - Wellcome Trust Research Programme (KWTRP), the Medical Research Council at the Uganda Virus Research Institute (MRC/UVRI), UVRI-IAVI and the Zambia Emory HIV Research Program (ZEHRP).
Africa-Europe partnership launched to develop new AIDS vaccine
Research
8 February 2017
A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide.